AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02390648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
Trial: NCT00373191
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N/A- not dictated by study
Trial: NCT00373191
Drug: endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N/A- not dictated by study
Trial: NCT00016276
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00016276
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02406794
Drug: Neuromuscular taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
Trial: NCT04470531
Drug: oral co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral co-trimoxazole + standard therapy
Trial: NCT02107079
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: swallowing 1 piece, collecting saliva afterwards
Trial: NCT00399737
Drug: repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00396461
Drug: MCT/LCT (1:1)
RxNorm normalized name: lipid emulsion MCT/LCT (1:1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion based on 20% MCT/LCT (50:50 ratio)
Trial: NCT00396461
Drug: MCT/LCT/omega-3 (5:4:1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
Trial: NCT01245036
Drug: Antituberculous therapy along with steroids
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INH (300 mg/day) plus Rifampicin (450 mg/day if wt.\<50 kg and 600 mg/day if wt. \>50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
Trial: NCT01615887
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT01983514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02450526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 Units
Trial: NCT02450526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 Units
Trial: NCT01001260
Drug: No ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative antiplatelet therapy instead of aspirin
Trial: NCT03064438
Drug: ACCU-D1
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACCU-D1
Trial: NCT03064438
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT01059786
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of infusion-related symptoms with acetaminophen is recommended.
Trial: NCT04130178
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: block of the digital nerves in rheumatoid arthritis patient
Trial: NCT02668822
Drug: ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicated vaginal ring
Trial: NCT02668822
Drug: Placebo vaginal ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal ring
Trial: NCT02668822
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
Trial: NCT01059786
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Trial: NCT01543555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
Trial: NCT00521989
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone
Trial: NCT00521989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01059786
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Trial: NCT01059786
Drug: Bronchodilators
RxNorm normalized name: ANTIASTHMA/BRONCHODILATORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional treatment with bronchodilators may be indicated.
Trial: NCT00098228
Drug: QAB149
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00385788
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
Trial: NCT02036463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00384384
Drug: oral 18B Glycyrrhetinic acid versus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01739634
Drug: CASAD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CASAD is provided in 500mg capsules.
Trial: NCT02572349
Drug: IW-1701
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02572349
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00483548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
Trial: NCT01294566
Drug: GSK1322888
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg, 5 mg or 25 mg capsule
Trial: NCT01294566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsules
Trial: NCT00455416
Drug: Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mgx5 daily
Trial: NCT04692025
Drug: ASC41 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT01005706
Drug: rapamune, mycophenolate mofetil and steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator.
Trial: NCT04549922
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mL subcutaneous
Trial: NCT02062801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
Trial: NCT01466322
Drug: GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
Trial: NCT02507284
Drug: SRX246
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02507284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01258088
Drug: AN2728 Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg/cm2, BID
Trial: NCT02290093
Drug: Standard full-volume PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.
Trial: NCT02790034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
Trial: NCT00548379
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olive oil 1ml
Trial: NCT02658916
Drug: BIIB092
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same dose as corresponding CN002003 study panel.
Trial: NCT03418857
Drug: Yogurt smoothie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the one month control period, the participants will consume one yogurt smoothie daily.
Trial: NCT02499224
Drug: YYB101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development
Trial: NCT04102241
Drug: 15mg Hemay005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemay005 is a small molecule PDE4 inhibitor.
Trial: NCT04102241
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos are the same as drugs, but contain no Hemay005.
Trial: NCT03712241
Drug: K-285
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT03712241
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT01842126
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending Doses intravenous (IV) of Placebo
Trial: NCT01842126
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending Doses subcutaneous (SC) of placebo
Trial: NCT02106650
Drug: Folotyn and Leucovorin
RxNorm normalized name: Folotyn
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02106650
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
Trial: NCT02594371
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00070616
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01280617
Drug: Thymoglobulin 0.75mg/kg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin
Trial: NCT02290093
Drug: Split-dose full-volume PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
Trial: NCT02290093
Drug: Split-dose low-volume PEG
RxNorm normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
Trial: NCT02439203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00573170
Drug: TREXIMET®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)
Trial: NCT00573170
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00733031
Drug: AZD6918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid suspension, daily, oral dose
Trial: NCT03878888
Drug: Exparel 266 MG Per 20 ML Injection
RxNorm normalized name: Exparel 266 MG per 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receive Exparel in bilateral TAP blocks for open abdomen surgery
Trial: NCT00964288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To match GSK drug and positive control
Trial: NCT02199678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00971737
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02224573
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00296491
Drug: placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle placebo nasal spray
Trial: NCT00296491
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule
Trial: NCT00296491
Drug: placebo DISKUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo DISKUS
Trial: NCT01934738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, TID or titration, 14 days
Trial: NCT02407171
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg every 2 weeks by IV infusion
Trial: NCT01546649
Drug: TAP-144-SR(3M)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03645499
Drug: Topical TA-102 C
RxNorm normalized name: Xoten-C Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Trial: NCT01643226
Drug: placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0% riboflavin ophthalmic solution
Trial: NCT03714555
Drug: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
Trial: NCT02433119
Drug: CODIOVAN® 160/12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01570348
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01570348
Drug: Mycophenolic Acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02011750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
Trial: NCT01907880
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4mg IV every 4 weeks for 3 cycles
Trial: NCT01907880
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03649412
Drug: GSK2982772 Modified Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.
Trial: NCT03649412
Drug: GSK2982772 Immediate Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
Trial: NCT03738527
Drug: Normal Saline Flush, 0.9%, 20mL topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure
Trial: NCT01434576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
Trial: NCT01849016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00285584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
Trial: NCT00567476
Drug: Inhaled corticosteroids (ICS)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent
Trial: NCT00567476
Drug: Short-acting beta 2-adrenergic agonist (SABA)
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
Trial: NCT01128582
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
Trial: NCT04272476
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04661826
Drug: Oncofid-P-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
Trial: NCT01373060
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01373060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02696031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
Trial: NCT04403763
Drug: AGN-241622
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eye drop
Trial: NCT04403763
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eye drop
Trial: NCT04047563
Drug: PMZ-1620 (sovateltide) along with standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Trial: NCT00749502
Drug: MK-4827
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
Trial: NCT03060850
Drug: AC0010MA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
Trial: NCT01376310
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 2 mg/day
Trial: NCT02187107
Drug: rtv
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet of Norvir®
Trial: NCT03913260
Drug: LY3375880
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00711841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
Trial: NCT02786719
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CYCLE 1+2 (given by intravenous catheter daily for 5 days)